Moore Regional Hospital, part of Carolinas’ health system FirstHealth, was the first trial site organization to enroll a patient in a clinical trial involving a regimen for COVID-19 including remdesivir and antibodies designed to neutralize COVID-19. Led by Principal Investigator Gretchen Arnoczy, MD, an infectious disease physician with FirstHealth, the accomplishment is monumental given the scope of this National Institute of Allergy and Infectious Diseases (NIAID) sponsored global multicenter clinical trial called Inpatient Treatment with Anti-Coronavirus Immunoglobulin or ITAC.
Sponsored by the University of Minnesota in collaboration with NIAID, NIH and the International Network for Strategic Initiatives in Global HIV Trials, this study’s protocol serves as a platform for investigating treatments for adult patients hospitalized for medical management of COVID-19 without related serious end-organ failure. Trials involve sites worldwide strategically selected to expedite enrollment.
In the study, the principal investigators will compare hyperimmune intravenous immunoglobulin (hiVIG) with matched placebo, when added to standard of care (SOC), for preventing fu...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).